Actively Recruiting

Age: 18Years - 80Years
All Genders
ID06614114

Albumin Bilirubin Index as a Predictor of Outcome of Variceal Bleeding

Led by Assiut University · Updated on 2024-09-26

48

Participants Needed

1

Research Sites

34 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating the albumin bilirubin index to predict the risk of recurrent bleeding within three months after endoscopic treatment in patients with cirrhosis and esophagogastric variceal bleeding (EGVB). The study aims to clarify how well this index can forecast bleeding outcomes, which may help guide future care for affected patients. The research is observational and sponsored by Assiut University. Participants will be observed following their endoscopic treatment without receiving additional experimental interventions. The study focuses on monitoring patients over time to evaluate the relationship between their albumin bilirubin index levels and bleeding recurrence. No specific treatments or procedures beyond standard care are assigned by the study. During the study, participants' health and bleeding status will be regularly assessed to track the prevalence of variceal bleeding in those with a high albumin bilirubin index over six months. Data collection will include clinical evaluations and laboratory tests as part of routine care. The study duration and follow-up are structured to gather meaningful information on this predictive marker's value.

CONDITIONS

Brief Title

Albumin Bilirubin Index as a Predictor of Outcome of Variceal Bleeding

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 80 years old
Not Eligible

You will not qualify if you...

  • Hepatocellular carcinoma (HCC)
  • Hematological disease

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Monitoring

Duration - 3 months

Participants are observed to clarify the predictive value of albumin bilirubin index for recurrent bleeding within 3 months after endoscopic treatment.

Trial Site Locations

Total: 1 location

1

Assiut university hospital

Asyut, Egypt, Assiut

Actively Recruiting

Loading map...

Research Team

H

Heba Sayed Zaki

A

Ahmed M.Ashmawy

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here